These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 2596061)
1. [Study of DNA content using a flow cytometry method and steroid hormone receptors in breast cancer]. Zubrikhina GN; Kuz'mina EV; Bassalyk LS; Murav'eva NI Vopr Onkol; 1989; 35(10):1179-86. PubMed ID: 2596061 [TBL] [Abstract][Full Text] [Related]
2. [Assay of DNA content and estrogen receptor status in human breast cancer]. Chen GJ; Shao YF; Shan Y Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):461-4. PubMed ID: 7720507 [TBL] [Abstract][Full Text] [Related]
3. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328 [TBL] [Abstract][Full Text] [Related]
4. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041 [TBL] [Abstract][Full Text] [Related]
5. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer. Kute TE; Muss HB; Anderson D; Crumb K; Miller B; Burns D; Dube LA Cancer Res; 1981 Sep; 41(9 Pt 1):3524-9. PubMed ID: 7020931 [TBL] [Abstract][Full Text] [Related]
6. Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Raber MN; Barlogie B; Latreille J; Bedrossian C; Fritsche H; Blumenschein G Cytometry; 1982 Jul; 3(1):36-41. PubMed ID: 7117052 [TBL] [Abstract][Full Text] [Related]
7. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685 [TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103 [TBL] [Abstract][Full Text] [Related]
10. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients]. Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437 [TBL] [Abstract][Full Text] [Related]
11. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953 [TBL] [Abstract][Full Text] [Related]
12. [Male breast cancer. Histochemical and flow cytometry analysis of 6 cases]. Galasso MG; Galia A; Gazzano G; Cosentino A; Castorina S Pathologica; 1995 Oct; 87(5):503-5. PubMed ID: 8868175 [TBL] [Abstract][Full Text] [Related]
13. Detection of 20q13 gain by dual-color FISH in breast cancers. Kobayashi Y; Esato K; Noshima S; Oga A; Sasaki K Anticancer Res; 2000; 20(1B):531-5. PubMed ID: 10769720 [TBL] [Abstract][Full Text] [Related]
14. [Content of 17 beta éstradiol, progesterone and glucocorticoid receptors in patients with benign breast diseases]. Bassalyk LS; Kuz'mina ZV; Murav'eva NI; Smirnova KD; Vishniakova VV Vopr Onkol; 1982; 28(7):3-6. PubMed ID: 7101825 [TBL] [Abstract][Full Text] [Related]
15. DNA proliferative index as a marker in Iraqi aneuploid mammary carcinoma. al-Alwan NA East Mediterr Health J; 2000; 6(5-6):1062-72. PubMed ID: 12197329 [TBL] [Abstract][Full Text] [Related]
16. DNA ploidy and survival in breast cancer patients. Cornelisse CJ; van de Velde CJ; Caspers RJ; Moolenaar AJ; Hermans J Cytometry; 1987 Mar; 8(2):225-34. PubMed ID: 3582068 [TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors and flow cytometric DNA ploidy in ovarian carcinoma. Grénman SE; Klemi P; Toikkanen S; Kaihola HL; Laippala P; Mäenpää J; Mäkinen J; Grönroos M Ann Chir Gynaecol Suppl; 1994; 208():15-9. PubMed ID: 8092763 [TBL] [Abstract][Full Text] [Related]
18. Image cytometry of aneuploidy, growth fraction (MoAb Ki-67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas. Charpin C; Andrac L; Lavaut MN; Andonian C; Fraterno M; Devictor B; Perez-Castillo A; Bonnier P; Piana L Anal Cell Pathol; 1990 Oct; 2(6):357-71. PubMed ID: 2275882 [TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]